TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Complete Patient Data Records Collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Discontinuation of baclofen due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: focal injury fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Observed AZD9977 concentration at 24 hours (C24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in vivo persistence of TIL after adoptive transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent miscarriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of grade ≥ 3 mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Pain immediately after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain 5 minutes after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Confirmed Relapse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC pain score in target knee at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC physical function score in target knee at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global rating of disease activity by patient at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of the hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain perceived by the patient
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of bone resorption marker CTx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of bone formation marker, BSAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients who prematurely discontinued therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombus Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numerical Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Standard deviation of blood phenylalanine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cognitive abilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in language abilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Short chain fatty acid (SCFA) profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiota DNA profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiolucency of the periapical or furcation area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hip Dysfunction and Osteoarthritis Outcome Score (HOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability of study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Satisfaction with the Content of the CaringGuidance Summary Report Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functionality of the CaringGuidance Summary Report Form
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Usability of the CaringGuidance Summary Report Form
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to improvement on severity rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale for Depression-17 Item Minus Sleep Items
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of dyspnea
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported drunkenness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma ascorbic acid concentration area under curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microaspiration as Measured by Percentage of Tracheal Specimens Positive for Amylase Per Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of eligibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of acceptance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Carriage Prevalence of Disease Associated Genogroups of N. Meningitidis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Illness awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of patients with one or more DVTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Isokinetic muscle strength deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of Participants With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Non Vaccine Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Depth of coagulation in liver tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: frequency of headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores as assessed by the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Toxicity of DMXAA
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of DMXAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of DMXAA on coagulation parameters, TNF and other cytokine production, nitric oxide, and serotonin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reaction Time in EVO Gameplay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Conners' Adult ADHD Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of patients without bronchopulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total number of patients cured from SBP
Endpoint domain: Mortality/survival
Primary endpoint: Rate of premature birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Estimate of liver signal measured by MR spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Moderate-to-vigorous physical activity (student)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate-to-vigorous physical activity (teacher)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of non-progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: safety of infusing ex vivo cytokine-primed ALDHbr cells
Endpoint domain: Adverse events/effects
Primary endpoint: Recall rate for screening breast ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Elimination half-life (T½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Valsartan concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with undetectable plasma HBV DNA load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in PaO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Achieved Neutrophil Engraftment After Drug Product Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Height Standard Deviation Score for Chronological Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients starting bisphosphonate treatment within 6 months of fracture
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical episodes of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Monocyte-to-High-Density Lipoprotein Cholesterol Ratio changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Body Mass Index (BMI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in Global Power Doppler Ultrasonography (PDUS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Earliest Time Point at Which Improvement of Core Component of the Global PDUS in the MCP (2-5) Joints Was Assessed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported patient perception of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of subjects with improved CIS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Sensory Neuropathic Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete pathological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reproducibility of CBC parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Repeatability of CBC parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neutralizing Antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sciatic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Vitreomacular adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Weeks Spent With Clinically Significant Mood Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax of Telavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vss of Telavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLobs of Telavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of Telavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference From Baseline in Visual Analog Scale Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CTC density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CTC clusters density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Maintaining Steroids-free Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum concentrations of phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentrations of protein fermentation metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distress over six months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sentence Reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extrinsic tooth-stain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 30 Second Sit-to-Stand (STS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gait Speed (Meters Per Second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cell-free viral load and/or cell-associated proviral load in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: concentration of vitamins A, B12, and E in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: subclinical mastitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence, intensity, relationship and seriousness of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-emergent changes in vital signs and laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent changes in sensory and motor examination of the foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treatment-emergent changes at injection site (erythema and edema)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in adherence to Non Invasive Ventilation (NIV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient reported efficacy of botulinum toxin treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ferritin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of post-operative wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mid Arm Circumference Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Repair failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of participant engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Sinonasal Outcome Test-22 Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects with plasma HIV-1 RNA levels < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Exercise Capacity (Peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Submaximal Exercise Capacity (Exercise Time at 75% of Peak Workload)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Molecular markers of the estrogen pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Modified Ashworth Scale (MAS) grade of the plantar flexor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cumulative Incidence of Grade 2 to 4 Acute Graft vs Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Mechanical Axis Alignment Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemodenervation in injected muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Correct qEEG Evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum level of Hyaluronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurements of pepsin and pH in the Exhaled breath condensate (EBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurements of pepsin and bile salts in bronchoalveolar lavage (BAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum KL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse (MDE)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of cocaine abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability and Reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of colds followed by exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 25% Improvement on Whiteley Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 25% Improvement on H-YBOCS-M
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hamilton Depression Scale (HAM-D) score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Beck's Depression Inventory (BDI) score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Triglyceride change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first occurrence of PD-related infection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in skin toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Non-carboxylated osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immediate Active effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood cellular NAD+ concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six minutes walking endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Alkaline Phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Completion of Core Vitrectomy and Shave of Vitreous Base
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in CD4 percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patent Foramen Ovale size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Dynamic Arterial Elastance (Eadyn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantitative Sensory Testing (QST) of an affected area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in the detection of foetal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reliability in the detection of foetal movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of motor function, cognition and/or seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of Tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of acute graft versus host disease (aGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Standardized Uptake Value (SUVmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Standardized Uptake Value (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of unplanned healthcare utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical Assessment of Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes